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Abstract
Socioeconomic status (SES) is defined as an individual’s social or economic standing, and is a measure of an individual’s or
family’s social or economic position or rank in a social group. It is a composite of several measures including income, education,
occupation, location of residence or housing. Studies have found a lower SES has been linked to disproportionate access to
health care in many diseases. There is emerging data in pulmonary diseases such as COPD, asthma, cystic fibrosis, pulmonary
hypertension and other chronic respiratory conditions that allude to a similar observation noted in other chronic diseases. In the
setting of COPD, SES has an inverse relationship with COPD prevalence, mortality, health utilization costs and HRQoL. Asthma
and cystic fibrosis show an increased severity and hospitalizations in relationship to a lower SES. Similar observations were seen
in sarcoidosis, PHTN and obstructive sleep apnea. There remains a limited data on non-CF bronchiectasis and interstitial lung
diseases. Population SES may be gauged by various measures such as education, occupation, marital status but no value is more
indicative than income. Currently guidelines and management algorithms do not factor the effect of SES in the disease process.
Despite the great amount of data available, a standardized method must be created to include SES in the prognostic calculations
and management of chronic pulmonary diseases.
Key words: socioeconomic status; pulmonary disease; disease severity; access to health care; chronic respiratory disease
Adv. Respir. Med. 2017; 85: 97–108

Introduction
Socioeconomic status (SES) is defined as an
individual’s social or economic standing, and is
a measure of an individual’s or family’s social or
economic position or rank in a social group [1].
It is generally a composite of several measures
including income, education, occupation (including employment status), location of residence,
housing (including home amenities), and may also
include participation in social organizations [1–3].
Of all the measured demographics in healthcare
today, SES may be the least reported but the most
influential in a patients’ access to healthcare and

clinical outcomes [4]. Globally healthcare coverage of every country’s individual populations is
varied. In the United States which uses a combination of private and government sponsored health
insurance, is in contrast to other countries which
provide nationalized health coverage or none at
all. However, despite efforts by many national
governments to provide all members of society
with access to healthcare, SES still has a profound
effect on life expectancy and is still independently
a risk factor for death as higher income is associated with greater longevity [5].
To the best of our knowledge studies across
all fields of medicine have found a lower SES
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Table 1. Traditional measures of socioeconomic status [16]
Occupation
— employment status (e.g., employed/unemployed/retired)
— specific occupational group
— aggregate occupation groups
— blue-/white-collar workers
— employment status
Education
— years of education (aggregate)
— highest educational level completed (i.e. High School,
College, etc)
— credentials earned (e.g., high-school diploma, Bachelors
degree, graduate degrees)
Income
— individual annual income
— annual household income (aggregate)
— family income

has been linked to disproportionate access to
health care in many diseases, which leads to poor
health outcomes [6]. A comprehensive review
has found that there are increased risks relating
to cardiovascular disease as well as access to invasive cardiac procedures [7, 8], chronic kidney
disease [9], diabetes mellitus [10] as well as in
cancer survival [11]. There has been emerging
data in various pulmonary diseases that alludes
to a similar observation noted in other chronic
diseases [12–15]. This review attempts to clearly
outline the documented literature in regards
of socioeconomic status and its relationship to
common chronic respiratory diseases as well as
highlight the role of SES is advanced lung disease
as a barrier to access to health care.

Socioeconomic status and its domains
Socioeconomic status (SES) is defined as an
individual’s social and economic standing, and is
a measure of an individual’s or family’s social or
economic position or rank in a social group [1].
Traditional SES measures included occupation,
education and income [16]. Each of these measures captures a distinct aspect of SES and may
be correlated with other measures but are not
easily interchangeable due to their finite nature.
However, obtaining traditional measures of
SES outlined in Table 1 may not always be feasible
due to missed recordings, personal nature of questions, discrepancies in reporting, instructional
review board constraints. In addition, as SES in
epidemiological studies in often retrospective [16]
relying on traditional measures may lead to a bevy
of missing data. For this reason surrogates for
the measurement of SES have been formulated.
98

These forms of SES measures are referred to as
contextual measurements.
Contextual measures of SES focus on ecological and geographic variables or may involve
a combination of both. Contextual approaches to
SES examine the social and economic conditions
that affect all individuals who share a particular
social environment or which they live in. Access
to goods and services, the built environment, and
social norms and other factors relevant to health
are often determined by the community [17].
Researchers and public health officials have acknowledged that the context in which one lives
also contributes to health [18, 19]. Examples of
contextual measures of SES may be at the neighborhood level and include ZIP codes, census
tracts, census block groups or census blocks. It
may also include other geographic areas such as
counties, regions and states [16].
The accuracy of these measures in terms of
SES within the census tract, ZIP code, county
or other community areas can vary widely depending upon the amount of time that has passed
since these data were collected and the dynamic nature of the geographic area of interest (e.g.,
patterns of movement into and out of the area,
gentrification, changes in the industry, unemployment rates and so forth). In addition, racial/
/ethnic differences an underreporting in census data’
suggest that the reliability may not always be there.
Underreporting may occur in special populations
such as migrants and the undocumented populations who are not accounted for in census and
epidemiological studies. A proposed relationship
between SES and healthcare delivery in the setting
of chronic respiratory disease has been shown in
Figure 1.

Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease
(COPD) is a chronic disease characterized by poor
outward airflow from the lungs. Tobacco smoking
is most commonly implemented in the pathogenesis. As a disease with a reversible component,
SES plays an important role as access to care may
reverse or stop progression of the disease. COPD
outcome disparities have been attributed to many
factors associated with SES such as smoking, occupation, environmental pollution and developmental factors such as childhood infections and
asthma [20]. Often environmental factors are also
associated with SES living conditions. Extensive
research has been conducted to determine if SES
affects the status and risk of developing COPD and
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Figure 1. Proposed relationship between socioeconomic status (SES) and healthcare delivery in the setting of chronic respiratory disease

mortality [12]. Studies analyzing SES and COPD
have been outlined in Table 2.
Chronic obstructive pulmonary disease is one
of the most common chronic respiratory disorders
and multiple studies have found its prevalence to be
higher in the lower SES population. In a preliminary
study of NHANES surveys, Whittemore et al. [30]
reported a significant inverse relationship between
income and COPD for both men and women. Various
authors have found that household income was an
important determinant of the prevalence of COPD
and that the prevalence of COPD was significantly
higher among respondents from lower income
households for both men and women [21, 24, 26].
As demonstrated, SES plays a pivotal role
in severity of COPD. There may be many factors
that contribute to this phenomenon. COPD is
strongly linked to the use of tobacco. It has been
found that smoking prevalence continues to be
higher among socially disadvantaged groups [31]
and that smoking itself may in fact be a better
predictor of long term survival than SES [32].
Taking this into consideration it is also plausible
that smoking cessation options might not be as
readable available to this population due to cost.
It has been observed by Broms et al. [33] that
a higher SES as measured by education and social
class was associated with higher rates of smoking
cessation. The relationship of tobacco use and
cessation plays a key role in inverse relationships
seen between SES and COPD.

In addition to disease severity measures it
has been found that SES plays an integral role
in mortality. In a study by Gershon et al. [28],
based purely on household income in a single
payer healthcare system, it was found that there
was statistically significant difference in the mortality difference between the lowest and highest
income quintiles. Mortality increased from 67
per 10,000 individuals in 1996–1997 to 86 per
10,000 individuals representing a 28% relative
increase. It was also observed that mortality in
people with COPD has decreased faster in people
with the highest compared with the lowest SES,
causing increased disparity between rich and
poor. Further study and strategies are needed to
explore and address factors responsible for this
increasing disparity in the COPD population [28].
Lewis et al. [25] analyzed traditional markers of
SES as well as other contextual measures and
determined that a lower household income and
educational status were independent risk factors
for mortality due to COPD.
Most recently a study by Cho et al. [29], the
first prospective study to demonstrate that individual and neighbor socioeconomic status play
a role in all-cause mortality of COPD patients.
Compared to high-income patients from advantaged neighborhoods, the adjusted hazard ratio
for middle-income COPD patients who lived in
advantaged and disadvantaged neighborhoods
was 1.22 (95% CI, 1.03–1.43) and 1.36 (95% CI,
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Table 2. Selected studies demonstrating relation of SES and COPD prevalence and mortality
Study

Year

Location

N

SES Measure (Source of SES Info)

SES Findings

Chen et al. [21]

2000

Canada

3654

Household Income
(National Population Health Survey)

↑ COPD prevalence
in lower SES

Welle et al. [22]

2004

Norway

1512

Education
(Patient Reported Occupation

↓ COPD prevalence
with ↑ SES

Steenland et al. [23]

2004

United
States

Employed
individuals
from 27 states

Occupation
(Nam-Powers scores for occupation)

↑ Rate of COPD
Mortality in ↓ SES

Schikowski et al. [24]

2008

Germany

1172

Education
(Self-administered standardized questionnaire)

↑ COPD prevalence
with ↓ SES

Lewis et al. [25]

2009

United
States

189924

Household Income
Education Level
Health Insurance
Marital Status
(National Longitudinal Mortality Study)

↑ Mortality risk in lower
SES based on Income
and Education

Kanervisto et al. [26]

2010

Finland

8028

Household Income
Education Level
(Health 2000 Survey)

↑ COPD risk in lower
SES

Yin et al. [27]

2011

China

49363

Household Income
Education Level
(China Chronic Disease Risk Factor Surveillance
in 2007)

↑ COPD prevalence in
lower SES

Gershon et al. [28]

2014

Canada

428046
807996

Household Income
(Canadian Census postal code)

Mortality rate ↓ faster in
higher SES as compared
to lower SES

Cho et al. [29]

2016

Korea

9275

Household Income
Neighborhood Deprivation
(Monthly Insurance Premium, 2005 Korean Census, Carstairs Index)

↑ Mortality in lower
SES individually and by
neighborhood

SES — socioeconomic status; COPD — chronic obstructive pulmonary disease

1.15–1.60), respectively. For low-income patients,
the adjusted HR for patients who lived in disadvantaged neighborhoods was higher than for
patients who lived in advantaged neighborhoods
(HR, 1.43; 95% CI, 1.17–1.74 vs. HR, 1.36; 95%
CI, 1.11–1.66).
As it has been demonstrated by various studies that prevalence as well as mortality is related
to variations in SES, another interesting aspect
of the disease is the health utilization costs. As
COPD is often complicated with exacerbations
requiring hospitalizations, assumption would
suggest that SES plays a role in hospitalizations
and the ultimate cost of healthcare. A study on
the geriatric population determined that COPD
hospitalization rate was inversely related to income in both males and females and that higher
income was associated with lower co-morbidity
[34]. A study in Canada, which utilizes a single
payer system, as in Poland, it was observed that
hospital admission rates for COPD patients in
a lower SES group were about three-fold higher,
than those in the high SES group. This alludes
100

to the fact that socioeconomic barriers exist in
access to healthcare or therapy.
Furthermore all chronic disease have a negative impact on health related quality of life
(HRQoL) which is defined as by the Center for
Disease Control as an assessment of how an individual’s well-being is being affected over time
by a disease, disability, or disorder. A study from
Spain by Miravitlles et al. [35] determined that
there was a gradient of impairment in HRQoL
according to the educational level, as well as in
more unskilled workers. HRQoL was measured
using EQ-5D and AQ20 questionnaires that assessed patient reported perception of “current
health”, the five dimensions of mobility, self-care,
usual activities, pain/discomfort, anxiety/depression and finally respiratory HRQoL in COPD.
There was a gradient of impairment in HRQoL
according to the educational level, with significantly worse scores for the EQ-5D and the AQ20
for medium and low educational levels compared
with high education. Similarly, HRQoL was also
significantly impaired in more unskilled workers
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Table 3. Selected studies demonstrating relation of SES and asthma
Study

Year

Location

N

SES Measure (Source of SES Info)

Relationship to SES

Mielck et al. [39]

1996

Germany

4434

Education Level (Parents)
(Modified American Thoracic Society Questionnaire)

↑ prevalence of severe
asthma in lower SES

Eagan et al. [40]

2004

Norway

2819

Education Level
(Hordaland County Cohort Study)

↑ risk in developing asthma
in lower SES

Basagana et al. [41]

2004

Inter
national

10971

Occupation
Education Level
(European Community Respiratory
Health Survey)

↑ prevalence of asthma
regardless of atopy in lower
SES

Ellison-Loschmann
et al. [42]

2007

Inter
national

9023

Occupation
Education Level
(European Community Respiratory
Health Survey)

↑ prevalence of asthma with
no atopy and ↑ traditional
asthma prevalence and incidence in lower SES

Ungar et al. [43]

2011

Canada

490

Family Income Adequacy
(National Population Health Survey)

↑ exacerbations in lower
SES families

SES — socioeconomic status

than skilled workers. These differences remained
significant after controlling for covariates [35].
In the setting of COPD the literature depicts
that when all variables are controlled, SES has
an inverse relationship with COPD prevalence,
mortality, health utilization costs and HRQoL.
Prevalence of disease is strongly associated with
tobacco use that is more common in socially disadvantaged populations [36]. Despite controlling
for cofounding factors there may be social aspects
of the disease that may not be accountable for that
influence mortality. In population with a lower
socioeconomic status, access to healthcare in
an issue that may lead to increased morbidity
and mortality. Not only is access to health care
a plausible reason for higher mortality rate in
the socially disadvantaged, access to smoking
cessation education and medication may also
play a role. Psychosocial aspects of disease, often
less explored, have also been influenced by SES.
Lower social classes have an inherent tendency
to experience a lower HRQoL [37] but in the setting of COPD, a chronic progressive debilitating
dyspneic disease, the role of SES in relation to
HRQoL may be more profound or easy to detect.

Asthma
Asthma is a chronic inflammatory condition
of the airways with many etiologies that has an
ill-defined relationship with SES. Comprehensive
studies have concluded that a lower socioeconomic position is in fact associated with asthma
severity and prevalence [38]. Asthma is often
addressed in the pediatric and young adult population so parent and guardian SES is assessed as

a surrogate for the patient. The studies that have
looked at asthma in relation to SES have been
outlined in Table 3.
A study that analyzed populations from Europe, USA, Australia and New Zealand surveying
patients using the European Community Respiratory Health Survey determined that prevalence
and incidence of asthma with no atopy were
associated with low educational level. Subjects
in the low occupational class (incident risk ratio
(IRR) 1.4; 95%CI 1.2–1.7) and education group
(IRR 1.3; 95% CI 1.1–1.6) had higher mean asthma
scores than those in higher socioeconomic groups
and that lower socioeconomic groups tended to
have a higher prevalence and incidence of asthma, particularly higher mean asthma scores [42].
In a study by Basagana et al. [41] using the same
survey found similar results, that asthma prevalence was higher in lower socioeconomic groups,
whether defined by educational level or social
class regardless of atopic status.
In addition to epidemiological findings it
has also been found that asthma disease severity
is linked to SES. A study by Mielck et al. [39]
examining the severity of asthma in children
looks at the SES of parents as assessed by their
highest education level determined. Prevalence
of severe asthma was found to be significantly
higher in the low as compared with the high
socioeconomic group and was not explained by
established risk factors. In a study by Eagan et
al. [40] it was determined that a lower education
level, which may be a used as a marker of SES,
was associated with a higher risk of developing
asthma. The adjusted OR (95% CI) for the incidence of asthma was 2.1 (1.01, 4.4) in subjects
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Table 4. Socioeconomic studies in cystic fibrosis
Study

Year

Location

n

SES Measure (Source of SES Info)

Relationship to SES

Britton et al. [44]

1989

United Kingdom

Variable

Occupation (non-manual
vs. manual professions)
(Office of Population Censuses and Surveys)

↑ age of death in non
manual occupations
(higher SES)

Schechter et al. [14]

1998

United States

261

Insurance type (Medicaid vs. Non-Medicaid)
(The National Cystic Fibrosis Foundation Patient Registry (NCFPR))

↑ Hospitalizations and
hospital days in lower
SES
↓ FEV1 in lower SES

Schechter et al. [45]

2001

United States

20390

Insurance type (Medicaid vs. Non-Medicaid)
(NCFPR)

↑ Risk of death and
hospitalization in lower
SES

O’Connor et al. [46]

2003

United States

23817

Zip Coded Based Median Household income
(1990 U.S. Census Data)

↑ incidence rate of
death in lower SES zip
codes
↓ FEV1 in lower SES

Quittner et al. [47]

2010

United States

6577

Insurance type (Medicaid vs. Non-Medicaid)
(Epidemiologic Study of CF)

↓ FEV1 in lower SES
↓ HRQOL Score in lower
SES

Stephenson et al.
[48]

2011

Canada

1174

Postal code based neighborhood income
(Statistics Canada census data)

No SES disparities
in hospitalization
in adult or pediatrics

SES — socioeconomic status; FEV1 — forced expiratory volume in one second

with a primary educational level, and 2.0 (1.04,
3.6) in subjects with a secondary educational
level as compared to subjects with a university
educational level. These were the findings after
adjustment for sex, age, hay fever, smoking, and
occupational exposure.
In an ideal situation the health disparities
that have been demonstrated in a multi-payer
health care system should, in theory not be seen
in a single payer healthcare systems. However
in a study by Ungar et al. [43] in the Canadian
universal healthcare system found that families
with a medium or high income adequacy had 28%
fewer exacerbations as compare to those with a low
income adequacy. The study from Ungar et al. [43],
in a single payer system, depicted that despite
universal healthcare coverage, asthma may not be
adequately managed in the socially disadvantaged.

Cystic fibrosis
Cystic fibrosis (CF) is a unique situation in
when patients are diagnosed from an early age.
There is also extensive follow up that provides
a good data set and the possibility to conduct
comprehensive longitudinal studies. This is
a genetic driven disease; however SES plays an
important role as a modifiable factor influencing
management, morbidity and outcomes. CF patients require extensive follow up and are prone to
lingering infections, which hamper their health.
102

Studies examining the role of SES in CF have been
outlined in Table 4. Early studies to examine the
social aspect of CF included a study by Britton
that showed that there was a trend for a higher age
of death in non-manual jobs for fathers or spouses of patients as compared to manual jobs. For
those who worked themselves, it was found that
manual workers had a better prognosis than those
non-manual workers [44]. This preliminary study
started a dialogue on the possible effects of SES
on CF disease. One of the initial studies looking
at CF disease severity and its relationship to SES
was a study by Schechter and Margolis that found
Medicaid patients, representing a lower SES, have
worse lung function and required more treatment
for pulmonary exacerbations than their more
advantaged counterparts [14]. This difference appeared to begin early in life, did not increase with
age, and was not explained by inadequate access
to outpatient specialty care or delayed diagnosis.
The study also offered other explanations to their
findings such as inadequate access to primary
care, poor adherence to prescribed regimens, and
possible greater exposure to pollutants (e.g., environmental tobacco smoke) are speculative [14].
In a follow up study by Schechter et al. [45] it
was found that the adjusted risk of death was
3.65 times higher for Medicaid patients than for
those not receiving Medicaid and those Medicaid
patients were 1.60 times more likely to require
treatment for a pulmonary exacerbation.
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Not only has socioeconomic status been implemented in disease severity but it has also been
shown to affect mortality. In a study by O’Connor
et al. [46] there was a strong association between
the median household income and the mortality
rate before and after adjusting for a variety of
patient and disease characteristics. In addition
patients living in lower median household income
area demonstrated lower pulmonary function
and body weight than did those living in higher
income areas.
There is a unique aspect of psychosocial
medicine in regard to CF. It is a disease that often
affects children and is associated a high level
of burden with an emphasis of health related
quality of life (HRQoL). SES, in general affects
quality of life, as it is often measure by income,
education, family size, occupation, etc. A study
by Quittner et al. [47] looked at the impact of SES
on the quality of life of CF patients. In general it
was found that patients with Medicaid, a marker
for low SES, all aged patients had worse lung
function and worse patient reported outcomes
according to the Cystic Fibrosis Questionnaire
Revised (CFQ-R).
In refractory CF disease, lung transplantation
remains a treatment option for those patients in
end stage lung disease. Criteria for lung transplantation in the CF population are based on
many factors including guidelines set forth by
the International Society for Heart and Lung
Transplantation [49]. Socioeconomic status as
measured by zip code median house hold income,
education level as well as Medicaid insurance
have all independently associated with not being
accepted for lung transplantation despite meeting all the criteria [50]. In fact a study by Ramos
et al. [51] has found that a low SES is a predictor
of non-referral for lung transplantation. This has
to be examined further as a study by Stephenson
et al. [48] showed that despite varying neighborhood SES there were no disparities in hospitalization rates in a large Canadian pediatric and
adult CF cohort.
Cystic fibrosis, due to its early diagnosis in
a pediatric population provides an ideal situation
for comprehensive follow up and longitudinal
studies. Though SES does not affect incidence,
as this is a genetic disease, it is evident overall
lung function is lower in lower SES groups. It
has also been noted that that risk of hospitalizations and duration of hospital stays are longer in
a lower SES. This observation may allude to the
fact that there may be social aspects that prevent
proper follow up or access to medications. The

continuality of irregular follow up is the increased
risk of death, which has been noted in multiple
studies. There is evidence that a lower SES, as
measured by income as well as type of insurance
is an independent risk factor for death in the setting of CF. Furthermore as this is a progressively
worsening disease the definitive treatment is
lung transplant. Multiple studies have shown
that definitive treatment may be hindered due to
a lower SES. Despite the uniformity of data on
the relationship of SES and CF, there still seems
to be a barrier to adequate care.

Sarcoidosis
Sarcoidosis is a granulomatous disorder of
unknown etiology that may affect any organ in the
body but most often affects the lungs, lymph nodes,
skin, and eyes, respectively. The disease exhibits
two distinct clinical courses: an acute course
that usually resolves or stabilizes within 2 years,
and a chronic course that is progressive and may
lead to severe organ dysfunction and death [52].
Sarcoidosis severity has shown a geographic
variation as well as more advanced disease in municipal hospitals versus private hospitals [53, 54].
These observations in some part have been attributed to SES. Studies analyzing sarcoidosis in
relationship to SES have been outlines in Table 5.
In the first study to look at disease severity in
correlation with SES was Rabin et al. [55]. It was
observed that a lower SES and no or public insurance were associated with worse health status
and more severe dyspnea. More advanced radiographic stage was associated with lower income,
and forced vital capacity impairment with less
education [55]. Patients who had incomes less
than $20,000 a year were 3.5 times more likely
to have Stage 3–4 disease than patients with an
income greater than $50,000 a year. Patients with
the highest incomes were more likely (36% vs.
7%) to have Stage 1 disease than patients with
the lowest incomes. Physical and social activity
limitations due to physical and emotional disability were related to no or public insurance
and lower income, but not education. Sarcoidosis
severity is associated with socioeconomic status
and insurance indicators; no or public insurance
and low income are associated with functional
limitations [55].
To confirm the previous study Rabin et al. [56]
set out to determine sarcoidosis disease severity
at first presentation. The results of the study
showed that lower income, the absence of private or Medicare health insurance were associ-
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Table 5. Socioeconomic studies in sarcoidosis
Study

Year

Location

N

SES Measure (Source of SES Info)

Relationship to SES

Yeager et al. [53]

1999

United States

91

Use of Private Hospital vs. Municipal
Hospital
Insurance Status

↑ disease stage and ↓ lung
function in lower SES

Rabin et al. [55]

2001

United States

110

Household Income
Education Level
Insurance Type (Sarcoidosis Telephone
Survey Form; Nation Health Interview
Survey)

↓ SES is associated with
more severe disease and
functional limitation

Rabin et al. [56]

2004

United States

696

↓ SES is associated more seIncome
Education
vere disease at presentation
Insurance Type (ACCESS Questionnaire [57]

SES — socioeconomic status

ated with sarcoidosis severity at presentation, as
were race, sex, and age. African Americans were
more likely to have severe disease by objective
measures, while women were more likely than
males to report subjective measures of severity.
Older individuals were more likely to have severe disease by both measures. In conclusion, it
was found that low income and other financial
barriers to care are significantly associated with
Sarcoidosis severity at presentation even after
adjusting for demographic characteristics of race,
sex, and age [56].

Advanced lung diseases
Pulmonary hypertension

Pulmonary hypertension (PHTN) is a rare and
devastating disease characterized by progressive
increases in pulmonary arterial pressure and pulmonary vascular resistance that eventually leads
to right ventricular failure and death [58, 59].
It may due to various etiologies such as left heart
disease; parenchymal lung disease, chronic
thromboembolic disease, hematologic disorders
or it may be idiopathic in nature though the clinical picture of these patients is similar [60]. Of the
various groups of PHTN, pulmonary arterial hypertension (PAH), WHO Group I PAH is now pharmacologically treatable with many options [61].
For this reason, early diagnosis is critical for preventing disease progression. Unfortunately, the
diagnosis of PAH is often difficult to make and
can require multiple physician visits and referral
to a medical specialist (i.e., cardiologist, pulmonologist) with specific training in pulmonary vascular disease. Despite the emergence of effective
therapy, PAH is commonly at an advanced stage
when recognized. Studies have shown that there
is a delay in the recognition of PAH. One in five
104

patients in the REVEAL registry who were eventually diagnosed with PAH reported symptoms for
more than 2 years before their disease was recognized. It was also noted that younger individuals
and patients with histories of common dyspneic
disorders were more likely to experience delayed
PAH recognition [62].
Though the role of socioeconomic status SES
has not been as exhaustively explored in PHTN
as the aforementioned conditions, studies have
shown that all across all groups of PHTN, SES is
associated with a more severe disease at presentation [15]. A study by Talwar et al. [15] on 228
PHTN patients showed that as median income
decreased, the WHO FC at presentation increased,
signifying higher disease severity. A similar analysis was done of WHO Group I PAH patients and
there was again a negative relationship between
income and initial FC.
The reasoning for this observation seems to be
varied. Despite the development of numerous therapies over the past 20 years, the delay to diagnosis
has not decreased over the past 3 decades [63, 64].
One possible reason for the delayed diagnosis and
more severe disease at presentation for lower SES
individuals may be due to access to advanced diagnostic procedures. A Right heart catheterization
(RHC) is needed to make the diagnosis of PAH and
distinguish it from other forms of PHTN. RHC
is a costly, hospital-based, invasive procedure
and may not be readily accessible to people with
a lower SES [8]. SES not only plays a role in the
diagnosis and treatment of the disease, it also
has a profound effect on the clinical outcome of
these patients. In a study by Wu et al. [65] it was
found that a lower SES was strongly associated
with a higher risk of death in PAH independent
of other clinical characteristics, hemodynamics,
and treatment.
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Table 6. Socioeconomic studies in obstructive sleep apnea (OSA)
Study

Year

Location

N

SES Measure (Source of SES Info)

Relationship to SES

Greenberg et al. [68]

2004

United States

303

Voluntary vs. Minority Serving Hospital

↑ OSA with comorbidities and failure to follow up in lower SES

Bakker et al. [69]

2011

New Zealand

126

Individual Income
Education
Employment

↓ compliance with CPAP
therapy in lower SES

SES — socioeconomic status; CPAP — continuous positive airway pressure

Interstitial lung disease

Interstitial lung disease (ILD) is a group disease of the interstitium. It may be due to inhaled
substances, drug induced, infection related,
associated with connective tissue disease (CTD)
or idiopathic in nature [66]. Currently the authors are not aware of any other publications in
peer-reviewed journals that examine the role of
SES and idiopathic interstitial lung disease. The
majority of mention of SES pertains to the role
of SES in CTD related ILD. The most common
CTD associated with associated ILD are scleroderma, polymyositis, dermatomyositis, systemic
lupus erythematosus and rheumatoid arthritis.
In a study by Koduri et al. [67] it was noted that
in patients with rheumatoid arthritis associated
ILD, Risk of death was almost double in patients
with low socio-economic status.

Other chronic respiratory diseases
Obstructive sleep apnea

Obstructive sleep apnea (OSA) is a condition
that often requires subspecialist care and the use
of durable medical equipment (DMEs). Diagnosis
and management options are attained after costly
polysomnography and continuous positive airway
pressure (CPAP) testing. From this information
alone it is plausible that SES may play an important role in OSA. There is not much in the
literature about OSA and SES.
The main study, which looks at OSA in
respect to SES, was a study by Greenberg et al.
[68] In this study severity of OSA was assessed
at a voluntary hospital serving primarily middle
class individuals with health insurance and
a minority serving hospital treating primarily
uninsured lower SES individuals. It was found
that despite similar age and apnea hypopnea index, that the minority serving hospital patients
had a greater body mass index, higher daytime
systemic blood pressure, more comorbid medical
conditions, and a lower minimum sleep SaO2 than
the voluntary hospitals patients. It was also noted

that systemic hypertension, diabetes mellitus,
asthma, and congestive heart failure were more
prevalent in the patient group from the minority
serving hospital and that forty two percent of
these patients diagnosed with OSA failed to follow up for treatment as compared with 7% in the
voluntary hospital group. These findings suggest
that OSA may be an important factor contributing
to socioeconomic-based differences in morbidity
and mortality.
OSA is primarily treated with the use of CPAP
therapy. A lower socioeconomic status has also
been noted to be a risk factor for CPAP acceptance.
In a study by Bakker et al. [69] it was determined
that patients with low SES are less receptive to
CPAP treatment than groups with higher SES and
that patients who indicate a higher level of social
economic deprivation adhered less to CPAP therapy than those who have a better social economic
situation. There is still much more research that
needs to be conducted to solidify the role of SES
in OSA diagnosis, severity and management but
as per preliminary studies it appears as if SES
does play a role in the disease severity and management strategies (Table 6).

Non cystic fibrosis bronchiectasis

Bronchiectasis is often dealt with in a pediatric population especially in the CF population.
We have addressed the relationship of SES in
CF and have observed that it is more prevalent,
severe, and detrimental to HRQoL in a lower
SES, however not much is known on the adult
population and Non-CF related bronchiectasis in
conditions such as tuberculosis, HIV, mycobacterium avium infection. There is not much in the
literature regarding adult bronchiectasis and SES.
In one study by Roberts et al. [70] it was found
that exacerbations of bronchiectasis were more
common in patients who are socioeconomically
deprived. Exacerbations in the setting of bronchiectasis often warranted hospital admission and is
associated with high readmission and mortality
rates [70]. The paucity of data may be in part
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due to lack of recording socio-epidemiological
measures in non-CF bronchiectasis, though there
might be a relationship of individual disease
processes and SES.

4.

Conclusion

6.

Socioeconomic status, regardless of how it is
assessed continues to be an important measure that
correlates to access to healthcare. In the strata of
common chronic respiratory diseases we have seen
many advances in the way of pharmacotherapy,
diagnostic testing and management guidelines.
However SES remains to be the most influential
barrier to access to healthcare. SES has been associated with incidence, prevalence and has shown
its influences on disease severity and clinical outcomes. The greatest amount of data regarding SES
exists for the diseases that are considered the most
“manageable” by clinicians i.e. COPD and asthma.
An outlier to this is the data that has been collected
by the CF community that continues to research
their population to learn all social determinants
of the disease. However there remains a paucity of
data on advanced lung diseases such as pulmonary
hypertension and interstitial lung disease.
Despite the great amount of data available,
a standardized method must be created to include
SES in the prognostic calculations of disease. Currently guidelines and management algorithms do
not factor the effect of SES in the disease process.
However from the emerging data is clearly evident
that SES plays an important role in the risks,
morbidity, mortality, health related quality of life
and most importantly clinical outcomes. An effort
need to be made by governing bodies to account
for the impact SES has in the clinical outcomes
in common respiratory diseases. In advanced lung
diseases such as pulmonary hypertension and
interstitial lung disease a greater focus needs to
be placed on SES as it might be a modifiable risk
factor affecting access to healthcare.
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